<DOC>
	<DOCNO>NCT00287664</DOCNO>
	<brief_summary>Hepatorenal syndrome common complication cirrhotic patient . The prognosis patient HRS poor . It demonstrate vasoconstrictor agent ( Terlipressin ) plus albumin effective reversal treatment . However , previous study pilot study able give information improvement survival . This comparative randomized study delineate test efficacy terlipressin survival .</brief_summary>
	<brief_title>Treatment Hepatorenal Syndrome With Terlipressin Plus Albumin v Albumin</brief_title>
	<detailed_description>Phase 3</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>1 . Patients HRS type 1 2 serum creatinine &gt; 2 mg/dL 2 . Age 18 75 year 3 . Written informed consent . 4 . Absence exclusion criterion 1 . Hepatocarcinoma ( 3 nodule great 3 cm 1 nodule &gt; 5 cm ) 2 . Active infection systemic inflammatory response syndrome 3 . Respiratory cardiac dysfunction . 4 . Arteriopathy . 5 . Ischemic cardiopathy . 6 . Arterial hypertension ( &gt; 140/90 mmHg hospitalization )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>hepatorenal syndrome</keyword>
	<keyword>terlipressin</keyword>
	<keyword>albumin</keyword>
	<keyword>cirrhosis</keyword>
</DOC>